77
Participants
Start Date
August 31, 2011
Primary Completion Date
November 30, 2012
Study Completion Date
May 31, 2014
eribulin mesylate
Cohort I \& II: eribulin mesylate (E7389) 1.4 mg/m2 intravenously over 2 - 5 minutes on Day 1 and Day 8 for 4 cycles
capecitabine
Cohort 1: capecitabine 900 mg/m2 orally twice daily on Days 1 - 14 of a 21-day cycle for 4 cycles Cohort II: fixed dose of 1500 mg oral capecitabine twice daily, 7 days on then 7 days off for 4 cycles
Sciode Medical Associates, PLLC, d.b.a. Eastchester Center, The Bronx
New York Oncology Hematology, P.C., Albany
Virginia Oncology Associates, Norfolk
Cancer Centers of the Carolinas, Greenville
Northwest Georgia Oncology Centers, P.C., Marietta
Cancer Centers of Florida, Orlando
Texas Oncology-Lewisville, Lewisville
Texas Oncology-Medical City Dallas, Dallas
Texas Oncology-Dallas Presbyterian Hospital, Dallas
Texas Oncology-Methodist Charlton Cancer Center, Dallas
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
Texas Oncology-Paris, Paris
Texas Oncology-Tyler, Tyler
Texas Oncology-Fort Worth 12th Ave., Fort Worth
Texas Oncology- Denton South, Denton
Texas Oncology-Memorial City, Houston
Cancer Care Centers of South Texas, San Antonio
Texas Oncology-Austin Central, Austin
Arizona Oncology Associates, PC - HOPE, Tucson
Arizona Oncology Associates, PC - CASA, Tucson
Northwest Cancer Specialists, P.C., Vancouver
Yakima Valley Memorial Hospital/North Star Lodge, Yakima
Evergreen Hematology and Oncology, Spokane
Eisai Inc.
INDUSTRY